Synthesis in  Escherichia coli  and Characterization of Human Recombinant Erythropoietin with Additional Heparin-Binding Domain

A. S. Karyagina; T. M. Grunina; M. S. Poponova; P. A. Orlova; V. N. Manskikh; A. V. Demidenko; N. V. Strukova; M. S. Manukhina; K. E. Nikitin; A. M. Lyaschuk; Z. M. Galushkina; S. A. Cherepushkin; N. B. Polyakov; A. I. Solovyev; V. G. Zhukhovitsky; D. A. Tretyak; I. S. Boksha; A. V. Gromov; V. G. Lunin

doi:10.1134/S0006297918100061

Synthesis in Escherichia coli and Characterization of Human Recombinant Erythropoietin with Additional Heparin-Binding Domain

Authors: Karyagina A.S.¹^,2^,3, Grunina T.M.¹, Poponova M.S.¹, Orlova P.A.¹, Manskikh V.N.¹^,3, Demidenko A.V.¹, Strukova N.V.¹, Manukhina M.S.¹, Nikitin K.E.¹, Lyaschuk A.M.¹, Galushkina Z.M.¹, Cherepushkin S.A.⁴, Polyakov N.B.¹^,5, Solovyev A.I.¹, Zhukhovitsky V.G.¹, Tretyak D.A.⁶, Boksha I.S.¹^,7, Gromov A.V.¹, Lunin V.G.¹^,2
Affiliations:
1. Gamaleya National Research Center of Epidemiology and Microbiology
2. All-Russia Research Institute of Agricultural Biotechnology
3. Belozersky Institute of Physical and Chemical Biology
4. State Research Institute of Genetics and Selection of Industrial Microorganisms
5. Vernadsky Institute of Geochemistry and Analytical Chemistry
6. Moscow Technological University (Lomonosov Institute of Fine Chemical Technologies)
7. Research Center of Mental Health
Issue: Vol 83, No 10 (2018)
Pages: 1207-1221
Section: Article
URL: https://journals.rcsi.science/0006-2979/article/view/151738
DOI: https://doi.org/10.1134/S0006297918100061
ID: 151738

Cite item

Full Text

Open Access
Restricted Access

Access granted
Restricted Access

Subscription Access

Abstract
About the authors
References
Statistics

Abstract

Recombinant human erythropoietin (EPO) with additional N-terminal heparin-binding protein domain (HBD) from bone morphogenetic protein 2 was synthesized in Escherichia coli cells. A procedure for HBD-EPO purification and refolding was developed for obtaining highly-purified HBD-EPO. The structure of recombinant HBD-EPO was close to that of the native EPO protein. HBD-EPO contained two disulfide bonds, as shown by MALDI-TOF mass spectrometry. The protein demonstrated in vitro biological activity in the proliferation of human erythroleukemia TF-1 cell test and in vivo activity in animal models. HBD-EPO increased the number of reticulocytes in the blood after subcutaneous injection and displayed local angiogenic activity after subcutaneous implantation of demineralized bone matrix (DBM) discs with immobilized HBD-EPO. We developed a quantitative sandwich ELISA method for measuring HBD-EPO concentration in solution using rabbit polyclonal serum and commercial monoclonal anti-EPO antibodies. Pharmacokinetic properties of HBD-EPO were typical for bacterially produced EPO. Under physiological conditions, HBD-EPO can reversibly bind to DBM, which is often used as an osteoplastic material for treatment of bone pathologies. The data on HBD-EPO binding to DBM and local angiogenic activity of this protein give hope for successful application of HBD-EPO immobilized on DBM in experiments on bone regeneration.

Keywords

erythropoietin, Escherichia coli, heparin-binding domain

Username
Password
Remember me

Forgot password?	Register

Username
Password
Remember me

Forgot password?	Register

Synthesis in Escherichia coli and Characterization of Human Recombinant Erythropoietin with Additional Heparin-Binding Domain

Full Text

Abstract

Keywords

About the authors

This website uses cookies